Search

Author/Creator Peng, A.

2. S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7). (23rd June 2022)

Authors:
Sureda, A.; Westin, J.; Locke, F. L.; Dickinson, M.; Ghobadi, A.; Elsawy, M.; van Meerten, T.; Miklos, D. B.; Ulrickson, M.; Perales, M.-A.; Farooq, U.; Wannesson, L.; Leslie, L.; Kersten, M. J.; Jacobson, C. A.; Pagel, J. M.; Wulf, G.; Johnston, P.; Rapoport, A. P.; Gordon, L. I.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
112
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Assessment of Tocilizumab (Anti–Interleukin‐6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody‐Mediated Rejection and Transplant Glomerulopathy in HLA‐Sensitized Renal Allograft Recipients. Issue 9 (10th March 2017)

Authors:
Choi, J.; Aubert, O.; Vo, A.; Loupy, A.; Haas, M.; Puliyanda, D.; Kim, I.; Louie, S.; Kang, A.; Peng, A.; Kahwaji, J.; Reinsmoen, N.; Toyoda, M.; Jordan, S. C.
Journal:
American journal of transplantation
Issue:
Volume 17:Issue 9(2017)
Page Start:
2381
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗